Clinical Trials - June 17, 2019
New data from AstraZeneca’s ASCEND trial
The company has announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing Calquence (acalabrutinib) significantly prolonged the time patients live without disease progression in relapsed or refractory chronic lymphocytic leukaemia (CLL). The ASCEND trial compared Calquence with the physician’s choice of rituximab combined with […]
Clinical Trials - May 20, 2019
New data from AstraZeneca trial
The company has announced new data from its Novel START trial, an open-label trial designed to reflect real-world practice. The results demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma, reports the company. These results are published in the New England Journal of Medicine. Novel START trial The trial compared Symbicort Turbuhaler with […]
Pharma Business - May 9, 2019
AstraZeneca’s Qternmet XR approved in the US
The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control in adults with type-2 diabetes (T2D). The approval is based on two Phase III trials, which evaluated combinations of dapagliflozin and saxagliptin on a background […]
Clinical Trials - May 7, 2019
AstraZeneca trial met primary endpoint
The company has announced positive results from their Phase III ASCEND trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia (CLL). Results showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Calquence monotherapy compared to a combination regimen of rituximab plus physician’s choice of idelalisib or bendamustine. Importantly, the safety and tolerability of Calquence was consistent […]
Collaboration - April 30, 2019
AstraZeneca starts artificial intelligence collaboration
AstraZeneca and BenevolentAI has began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). Scientists from the two organisations will work side-by-side to combine AstraZeneca’s genomics, chemistry and clinical data with BenevolentAI’s target identification platform […]
Pharma Business - April 29, 2019
AstraZeneca’s Lynparza receives positive EU CHMP opinion
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending Lynparza (olaparib) as a 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer. The recommendation is for the use of Lynparza tablets as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial […]
